Written by Vivian Lei
Spoon Feed
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that block inhibitors of T-cell activation and function. They are increasingly used in different malignancies by removing inhibition of T-cell function. However, this also facilitates autoimmune activity against multiple organs. Autoimmune adverse events are most common during the first 12 weeks of therapy but may occur up to 6 months following treatment discontinuation.
Why does this matter?
More and more cancer patients are taking these agents. This review in JAMA Insights highlights the most common ICI toxicities that a clinician may encounter and what to do about them.
Primary mechanisms of ICIs include:
-
Inhibition of cytotoxic T lymphocyte antigen 4 (CTLA-4; i.e., ipilimumab)
-
Inhibition of programmed death 1 (PD-1; i.e., novolumab, pembrolizumab)
-
Inhibition of programmed death ligand 1 (PD-L1; i.e., atezolizumab, avelumab, durvalumab)
The high gravity beer of chemo drugs – disinhibited, disorderly T-cells
Here is a table of the most common side effects by organ system. High-dose steroid treatment is the main way to shut down the toxic effects.
<div
class="
image-block-outer-wrapper
layout-caption-below
design-layout-inline
combination-animation-none
individual-animation-none
individual-text-animation-none
"
data-test="image-block-inline-outer-wrapper"
>
<figure
class="
sqs-block-image-figure
intrinsic
"
style="max-width:1066px;"
>
<div
class="image-block-wrapper"
data-animation-role="image"
>
<div class="sqs-image-shape-container-element
has-aspect-ratio
" style="
position: relative;
padding-bottom:125.32832336425781%;
overflow: hidden;
”
>
